Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
Reported positive interim results from ongoing Phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell disease demonstrating proof of mechanism and proof of biology
Company plans to initiate enrollment in a Phase 1b clinical trial in sickle…
